Download PDF
CC BY 4.0 · Pharmaceutical Fronts 2022; 04(03): e197-e206
DOI: 10.1055/s-0042-1755454
Original Article

Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy

Yu-Hang Duan
1   Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, People's Republic of China
,
Yan-lin Bian
1   Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, People's Republic of China
,
Jian-Wei Zhu
1   Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, People's Republic of China
› Author Affiliations Funding This research was funded by the National Natural Science Foundation of China (Grant No. 81773621 and 82073751) and the National Science and Technology Major Project “Key New Drug Creation and Manufacturing Program” of China (Grant No. 2019ZX09732001-019).
› Further Information
Also available at
   Permissions and Reprints

Abstract

Many studies have confirmed that the human poliovirus receptor (PVR; CD155) is related to tumor cell migration, invasion, and thus tumor progression. A PVR receptor binds its ligand T cell Ig and the ITIM domain (TIGIT) to inhibit the function of T and NK cells, thereby allowing tumors to evade immune surveillance. In this study, two IgG1 monoclonal antibodies, anti-CD155 and anti-TIGIT, were expressed by the mammalian transient transfection system, then, antibody-dependent cell-mediated cytotoxicity, antibody-binding affinity, and antitumor efficacy were evaluated subsequently in vitro. In this work, protein A affinity chromatography was used for antibodies' purification. Analysis methods included Western blot, enzyme-linked immunosorbent assay, and flow cytometry. Our data suggested that both the two monoclonal antibodies have a purity of higher than 90%, and bound tightly to the antigen with dissociation constant (K d) and 50% effective concentrations (EC50) below micromolar range. Most notably, these antibodies promote antitumor activity of immune cells in vitro. Therefore, our study laid down the foundation for subsequent in vivo experiments for further evaluation.

Keywords

monoclonal antibodies - TIGIT - PVR - tumor immunotherapy - antibody-dependent cell-mediated cytotoxicity

Ethics Statement

The separation of PBMCs from healthy donors abides by the relevant agreements of the Changhai Hospital of Shanghai, and it conforms to the provisions of the Declaration of Helsinki in 1995 (16). Informed consent was obtained from all individual participants included in the study.




Publication History

Received: 27 April 2022

Accepted: 13 July 2022

Article published online:
02 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Reference

  • 1 O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 2019; 16 (03) 151-167
    CrossrefPubMedGoogle Scholar
  • 2 Igarashi Y, Sasada T. Cancer vaccines: toward the next breakthrough in cancer immunotherapy. J Immunol Res 2020; 2020: 5825401
    CrossrefPubMedGoogle Scholar
  • 3 Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 2018; 6 (01) 8
    CrossrefPubMedGoogle Scholar
  • 4 Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19 (11) 1423-1437
    CrossrefPubMedGoogle Scholar
  • 5 Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity 2020; 52 (01) 17-35
    CrossrefPubMedGoogle Scholar
  • 6 Yu X, Harden K, Gonzalez LC. et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009; 10 (01) 48-57
    CrossrefPubMedGoogle Scholar
  • 7 Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev 2017; 276 (01) 112-120
    CrossrefPubMedGoogle Scholar
  • 8 O'Donnell JS, Madore J, Li XY, Smyth MJ. Tumor intrinsic and extrinsic immune functions of CD155. Semin Cancer Biol 2020; 65: 189-196
    CrossrefPubMedGoogle Scholar
  • 9 Joller N, Hafler JP, Brynedal B. et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 2011; 186 (03) 1338-1342
    CrossrefPubMedGoogle Scholar
  • 10 Stanietsky N, Simic H, Arapovic J. et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 2009; 106 (42) 17858-17863
    CrossrefPubMedGoogle Scholar
  • 11 Zhang Q, Bi J, Zheng X. et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 2018; 19 (07) 723-732
    CrossrefPubMedGoogle Scholar
  • 12 Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol Immunother 2017; 66 (10) 1367-1375
    CrossrefPubMedGoogle Scholar
  • 13 Lupo KB, Matosevic S. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. J Hematol Oncol 2020; 13 (01) 76
    CrossrefPubMedGoogle Scholar
  • 14 Kučan Brlić P, Lenac Roviš T, Cinamon G, Tsukerman P, Mandelboim O, Jonjić S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol 2019; 16 (01) 40-52
    CrossrefPubMedGoogle Scholar
  • 15 Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 2012; 30 (05) 1158-1170
    CrossrefPubMedGoogle Scholar
  • 16 Ding K, Han L, Zong H, Chen J, Zhang B, Zhu J. Production process reproducibility and product quality consistency of transient gene expression in HEK293 cells with anti-PD1 antibody as the model protein. Appl Microbiol Biotechnol 2017; 101 (05) 1889-1898
    CrossrefPubMedGoogle Scholar
  • 17 Wang Z, Zhu J, Lu H. Antibody glycosylation: impact on antibody drug characteristics and quality control. Appl Microbiol Biotechnol 2020; 104 (05) 1905-1914
    CrossrefPubMedGoogle Scholar
  • 18 Grogan JL, Johnston RJ, Wu Y. et al. Inventors; Genentech Inc (Geth-C) Genentech Inc (Geth-C), assignee. New antibody comprising hypervariable regions and specifically binding to human T cell immunoglobulin and immunoreceptor tyrosine-based inhibition motif, used to treat immune related disorders e.g. non-small cell lung cancer. U.S. Patent 2018186875–A1; 10047158–B2
    Google Scholar
  • 19 Jonjic S, Kaynan NS, Mandelboim O. et al. Inventors; Yissum Res Dev Co Hebrew Univ Jerusalem (Yiss-C), assignee. New monoclonal antibody specific to human poliovirus receptor, useful for diagnosing and treating cancer, viral infection, and angiogenesis-related disease or disorder. U.S. Patent 2017149538–A1
    Google Scholar
  • 20 Gao J, Zheng Q, Xin N, Wang W, Zhao C. CD155, an onco-immunologic molecule in human tumors. Cancer Sci 2017; 108 (10) 1934-1938
    CrossrefPubMedGoogle Scholar
  • 21 Huang DW, Huang M, Lin XS, Huang Q. CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. OncoTargets Ther 2017; 10: 3817-3825
    CrossrefPubMedGoogle Scholar
  • 22 Johnston RJ, Comps-Agrar L, Hackney J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26 (06) 923-937
    CrossrefPubMedGoogle Scholar
  • 23 Zhang C, Wang Y, Xun X. et al. TIGIT can exert immunosuppressive effects on CD8+ T cells by the CD155/TIGIT signaling pathway for hepatocellular carcinoma in vitro. J Immunother 2020; 43 (08) 236-243
    CrossrefPubMedGoogle Scholar
  • 24 Sun R, Zhou Y, Han L. et al. A rational designed novel bispecific antibody for the treatment of GBM. Biomedicines 2021; 9 (06) 640
    CrossrefPubMedGoogle Scholar
  • 25 Kurtulus S, Sakuishi K, Ngiow SF. et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 2015; 125 (11) 4053-4062
    CrossrefPubMedGoogle Scholar
  • 26 Han JH, Cai M, Grein J. et al. Effective anti-tumor response by TIGIT blockade associated with FcγR engagement and myeloid cell activation. Front Immunol 2020; 11: 573405
    CrossrefPubMedGoogle Scholar
  • 27 Zhuo B, Li Y, Gu F. et al. Overexpression of CD155 relates to metastasis and invasion in osteosarcoma. Oncol Lett 2018; 15 (05) 7312-7318
    PubMedGoogle Scholar
  • 28 Stamm H, Oliveira-Ferrer L, Grossjohann EM. et al. Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. OncoImmunology 2019; 8 (12) e1674605
    CrossrefPubMedGoogle Scholar
  • 29 Liu L, You X, Han S, Sun Y, Zhang J, Zhang Y. CD155/TIGIT, a novel immune checkpoint in human cancers (Review). Oncol Rep 2021; 45 (03) 835-845
    CrossrefPubMedGoogle Scholar